ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 5, 2011, Pages 360-368

  Kenney, Susan ^a   Vistica, David T ^a   Stockwin, Luke H ^b   Burkett, Sandra ^a   Hollingshead, Melinda G ^b   Borgel, Suzanne D ^b   Butcher, Donna O ^c   Schrump, David S ^d   Shoemaker, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Developmental Therapeutics Program   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

alveolar soft part sarcoma cell line (ASPS 1); ASPS; Sarcoma

Indexed keywords

ADAM 9 PROTEIN; ADAM PROTEIN; BIXALOMER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SCATTER FACTOR RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E3 TYPE 1 FUSION; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ALVEOLAR SOFT PART SARCOMA; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPS 1 CELL LINE; CANCER CELL CULTURE; CELL AGGREGATION; CELL GROWTH; CELL ISOLATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION X; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE LOCATION; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; TISSUE SPECIFICITY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION;

ADULT; ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOGENICITY TESTS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; ONCOGENE PROTEINS, FUSION; SARCOMA, ALVEOLAR SOFT PART; SOFT TISSUE NEOPLASMS; TRANSLOCATION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 79959820514     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182002f9f     Document Type: Article

References (33)

1. Christopherson WM, Foote FW Jr, Stewart FW. Alveolar soft-part sarcomas: Structurally characteristic tumors of uncertain histogenesis. Cancer. 1952;5:100-111.
2. Folpe AL, Deyrup AT. Alveolar soft part sarcoma: A review and update. J Clin Pathol. 2006;59:1127-1132. (Pubitemid 44787132)
3. Soft Tissue sarcomas-SEER pediatric monograph. http:// www.seer.cancer.gov.
4. Heimann P, Devalck C, Debusscher C, et al. Alveolar soft-part sarcoma: Further evidence by FISH for the involvement of chromosome 17q25. Genes Chromosome Cancer. 1998;23:194-197. (Pubitemid 28402347)
5. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20:48-57. (Pubitemid 32142337)
6. Vistica DT, Hollingshead M, Borgel SD, et al. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol. 2009;31:561-570.
7. Kenney S, Vistica DT, Stockwin L, et al. Establishment and characterization of ASPS-1, a novel cell line derived from metastatic alveolar soft part sarcoma. Proc Am Assoc Cancer Res. 2009;50:978.
8. Stockwin LH, Vistica DT, Kenney S, et al. Gene expression profiling of alveolar soft part sarcoma (ASPS). BMC Cancer. 2009;9:22.
9. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst. 1990;82:1107-1112. (Pubitemid 20213250)
10. Li J, Mayne R, Wu C. A novel muscle specific beta 1 integrin binding protein (MIBP) that modulates myogenic differentiation. J Cell Biol. 1999;147:1391-1398.
11. Li J, Rao H, Burkin D, et al. The muscle integrin binding protein (MIBP) intereacts with alpha7 beta1 integrin and regulates cell adhesion and laminin matrix deposition. Dev Biol. 2003;261:209-219. (Pubitemid 36993827)
12. Vistica DT, Krosky PM, Kenney S, et al. Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma. J Pediatr Hematol Oncol. 2008;30: 46-52.
13. Lazar AJF, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res. 2007;13:7314-7321.
14. Giaccai AJ, Rankin EB. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15:678-685. (Pubitemid 351405072)
15. Rocha S. Gene regulation under low oxygen: Holding your breath for transcription. Trends Biochem Sci. 2007;32:389-397. (Pubitemid 47126857)
16. Reynolds PR, Mucenski ML, LeCras TD, et al. Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem. 2004;279:37124-37132. (Pubitemid 39129063)
17. O'Leary JJ, Shapiro RL, Ren CJ, et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res. 1999;5:181-187. (Pubitemid 29045192)
18. Clements MK, Jones CB, Cumming M, et al. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol. 1999;44:411-416. (Pubitemid 29455587)
19. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002;62:4316-4324. (Pubitemid 34827288)
20. Rapisarda A, Uranchimeg B, Sordet O, et al. Topoisomerase 1 mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Res. 2004;64:1475-1482. (Pubitemid 38235619)
21. Rapisarda A, Zalek J, Hollingshead M, et al. Scheduledependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004;64:6845-6848. (Pubitemid 39330988)
22. Ferrara N, Hillan KJ, Novatny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335. (Pubitemid 40848295)
23. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919-929.
24. Lazar AJ, Lahat G, Myers SE, et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: An immunohistochemical study utilizing tissue microarray. Histopathology. 2009;55:750-755.
25. Vistica DT, Kenney S, Burkett S, et al. Therapeutic targeting of the ASPL-TFE3 gene fusion in ASPS-1, a novel cell line derived from metastatic alveolar soft part sarcoma (ASPS). Proc Am Assoc Cancer Res. 2010;51:828.
26. Seidah NG, Chretien M. Pro-protein convertases of subtilisin/ kexin family. Methods Enzymol. 1994;244:171-188.
27. Rouille Y, Duguay SJ, Lund K, et al. Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: The subtilisin-like proprotein convertases. Front Neuroendocrinol. 1995;16:322-361.
28. Khatib AM, Siegfried G, Chretien M, et al. Proprotein convertases in tumor progression and malignancy. Am J Pathol. 2002;160:1921-1935.
29. Basak A. Inhibitors of proprotein convertases. J Mol Med. 2005;83:844-855. (Pubitemid 41598685)
30. Bontemps Y, Scamuffa N, Calvo F, et al. Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases. Med Res Rev. 2007;27:631-648. (Pubitemid 47282447)
31. Lahlil R, Calvo F, Khatib AM. The potential anti-tumorigenic and anti-metastatic side of the proprotein convertase inhibitors. Recent Pat Anticancer Drug Discov. 2009;4:83-91.
32. Stetler-Stevenson WG. The tumor microenvironment: Regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008;27:57-66.
33. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell. 2003; 114:171-180. (Pubitemid 36936911)